Capabilities by Region: United Kingdom

Greenhill has considerable advisory experience in the United Kingdom. Our Managing Directors and professionals have advised clients on transactions involving many of the leading companies in the region and have access to a vast network of corporate relationships throughout the United Kingdom.

Greenhill established its presence in the United Kingdom in January 1998 with the opening of a London office.

For more information on Greenhill’s advisory practice in the United Kingdom and our capabilities in the region, please contact President David Wyles or Head of U.K. M&A Dean Rodrigues in our London Office.

Below we highlight a few of the transactions on which we have advised in this region:

Recent Transactions

09-Apr-24
Undisclosed
United States flag
Target: 

Tegra’s Operating Entities in Honduras, El Salvador, and the U.S.

Korea flag
Acquiror: 
SAE-A Trading

Advising Tegra, a premier and leading near and onshore apparel manufacturer for sport, team, and performance apparel, on the sale of its operating entities in Honduras, El Salvador, and the U.S. to SAE-A Trading, a vertically integrated textile and apparel garment manufacturer

05-Apr-24
$820 million (AUD)
Australia flag
Target: 

illion Australia Pty Ltd

United Kingdom flag
Acquiror: 
Experian Plc

Advising Experian Plc, the world’s leading global information services company, on the acquisition of  illion Australia Pty Ltd, one of Australasia's leading consumer and commercial credit bureaus

14-Feb-24
Undisclosed
United Kingdom flag
Target: 

Huntswood CTC Limited

Acquiror: 
The Results Companies, LLC

Advised Huntswood CTC Limited, a business process and outsourcing company, on its sale to The Results Companies, LLC (“ResultsCX”), a global Customer Experience Management company backed by ChrysCapital

10-Aug-23
Undisclosed
United Kingdom flag
Target: 

Clinigen Ltd’s portfolio of Established Medicines

United Kingdom flag
Acquiror: 
CNX Therapeutics

Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners

14-Jul-23
$674 million
U.S.A., U.K. flags
Target: 

Juice Plus+

flag not available

Advised Juice Plus+, a global health and wellness company in the direct selling space on a comprehensive recapitalization transaction

Pages

show all